Center-Authored Papers

Filters: Author is Kublin, James  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Moodie Z, Metch B, Bekker L-G, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S, Mngadi K, Innes C et al..  2015.  Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.. PloS one. 10(9):e0137666. Abstract
E
Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD et al..  2013.  Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine.. The New England journal of medicine. Abstract
F
Rademeyer C, Korber B, Seaman MS, Giorgi EE, Thebus R, Robles A, Sheward DJ, Wagh K, Garrity J, Carey BR et al..  2016.  Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.. PLoS pathogens. 12(7):e1005742. Abstract
G
Chang H-W, Tartaglia LJ, Whitney JB, Lim S-Y, Sanisetty S, Lavine CL, Seaman MS, Rademeyer C, Williamson C, Ellingson-Strouss K et al..  2015.  Generation and evaluation of clade C simian-human immunodeficiency virus challenge stocks.. Journal of virology. 89(4):1965-74. Abstract
H
Corey L, Nabel GJ, Dieffenbach C, Gilbert PB, Haynes BF, Johnston M, Kublin J, Lane CH, Pantaleo G, Picker LJ et al..  2011.  HIV-1 vaccines and adaptive trial designs.. Science translational medicine. 3(79):79ps13. Abstract
I
Janes H, Gilbert P, Buchbinder S, Kublin J, Sobieszczyk ME, Hammer SM.  2013.  In Pursuit of an HIV Vaccine: Designing Efficacy Trials in the Context of Partially Effective Non-Vaccine Prevention Modalities.. AIDS research and human retroviruses. Abstract
L
Leitman EM, Hurst J, Mori M, Kublin J, Ndung'u T, Walker BD, Carlson J, Gray GE, Matthews PC, Frahm N et al..  2016.  Lower Viral Loads and Slower CD4 Decline in MRKAd5 HIV-1 Vaccinees Expressing Disease-Susceptible HLA-B*58:02.. The Journal of infectious diseases. Abstract
M
Jin X, Morgan C, Yu X, De Rosa S, Tomaras GD, Montefiori DC, Kublin J, Corey L, Keefer MC.  2015.  Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials.. Vaccine. 33(20):2347-53. Abstract
P
Hopkins KL, Laher F, Otwombe K, Churchyard G, Bekker L-G, De Rosa S, Nchabeleng M, Mlisana K, Kublin J, Gray G.  2014.  Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef Vaccine Induced Immune Responses.. PloS one. 9(8):e103446. Abstract
Latka MH, Fielding K, Gray GE, Bekker L-G, Nchabeleng M, Mlisana K, Nielson T, Roux S, Mkhize B, Mathebula M et al..  2012.  Pregnancy incidence and correlates during the HVTN 503 Phambili HIV vaccine trial conducted among South African women.. PloS one. 7(4):e31387. Abstract
Sandison TG, Homsy J, Arinaitwe E, Wanzira H, Kakuru A, Bigira V, Kalamya J, Vora N, Kublin J, Kamya MR et al..  2011.  Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial.. BMJ (Clinical research ed.). 342:d1617. Abstract
R
Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker L-G, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S et al..  2014.  Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.. The Lancet infectious diseases. 14(5):388-96. Abstract
S
Talley AK, Healy SA, Finney OC, Murphy SC, Kublin J, Salas CJ, Lundebjerg S, Gilbert P, Van Voorhis WC, Whisler J et al..  2014.  Safety and comparability of controlled human Plasmodium falciparum infection by mosquito bite in malaria-naïve subjects at a new facility for sporozoite challenge.. PloS one. 9(11):e109654. Abstract
Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally M, Novak RM et al..  2008.  Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 46(11):1769-81. Abstract
Nicholson O, Dicandilo F, Kublin J, Sun X, Quirk E, Miller M, Gray G, Pape J, Robertson MN, Mehrotra DV et al..  2011.  Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults.. AIDS research and human retroviruses. 27(5):557-567. Abstract
Churchyard G, Mlisana K, Karuna S, Williamson A-L, Williamson C, Morris L, Tomaras GD, De Rosa SC, Gilbert PB, Gu N et al..  2016.  Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants.. PloS one. 11(9):e0161753. Abstract
Gilbert PB, Grove D, Gabriel E, Huang Y, Gray G, Hammer SM, Buchbinder SP, Kublin J, Corey L, Self SG.  2012.  A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens. Statistical Communications in Infectious Diseases. 3(1)